Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833539 | 0.84 | HDAC6 (0.52) | MAPTALDH1A1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL7522351 | 0.81 | ALDH1A1 (0.58) | MAPTALDH1A1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL15166434 | 0.80 | NLRP3 (0.40) | ALDH1A1HDAC6LMNAKMT2ATSHR | |
| SCHEMBL15166438 | 0.77 | PKM (0.46) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL15166435 | 0.77 | HDAC6 (0.40) | ALDH1A1HDAC6LMNAKMT2ATSHR | |
| SCHEMBL15166439 | 0.76 | HDAC6 (0.49) | ALDH1A1HDAC6LMNAKMT2ATSHR | |
| SCHEMBL9223888 | 0.75 | HDAC1 (0.51) | HDAC6KMT2A | |
| SCHEMBL14847734 | 0.75 | PAX8 (0.47) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL8327704 | 0.75 | ALDH1A1 (0.42) | MAPTALDH1A1HDAC6KMT2ATSHR | |
| SCHEMBL4933280 | 0.75 | HDAC6 (0.45) | MAPTALDH1A1HDAC6LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760845-B1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760845-B1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9376425-B2 | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376425-B2 | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376425-B2 | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| WO-2013049250-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | MAPT 1967/4885ALDH1A1 553/4885HDAC6 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.